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Atheromatous renal artery stenosis (ARAS) is common -it is present in 15-30% of otherwise unselected patients with coronary, peripheral or cerebral vascular disease. 1 It is easy to find; in our unit, about 75% of cases selected only on clinical clues and basic ultrasonography have some degree of ARAS at angiography. However, it is much more difficult to identify patients in whom ARAS is contributing to morbidity because all the possible clinical manifestations of ARAS can also be caused by other complications of atheromatous disease (Table 1) .
This article will discuss clinical scenarios in which ARAS should be considered with a view to revascularisation. The increasing refinement and availability of computed tomography (CT) and magnetic resonance (MR) angiography make definitive investigation simpler and safer than traditional angiography. Duplex scanning of the renal artery may have a role, but it is highly operator-dependent and can be impossible in obese subjects even in skilled hands.
The introduction of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor antagonists (AIIRA) has both unearthed previously silent cases of ARAS and made the diagnosis more important. Drugs of both classes abolish AII mediated glomerular efferent arteriolar constriction which is vital to maintain glomerular filtration rate (GFR) when renal perfusion pressure is reduced. This loss of GFR is independent of the cause of reduced renal blood flow and is also seen in the presence of hypotension or hypovolaemia of any cause as well as in renal artery stenosis. The effect of these drugs is dose dependent to some extent, and their effect on renal function in ARAS may also be masked by intravascular volume overload and/or hypertension. If the drug is stopped promptly, the effect on renal function is normally fully reversible.
Specific management will not be discussed in this article, but patients with ARAS are likely to benefit from healthy lifestyle modifications, blood pressure lowering and statins.
ARAS as a cause of hypertension

Theoretical background
Reduced renal blood flow stimulates renal renin release, which in turn increases production of angiotensin II and aldosterone:
AII raises blood pressure by its potent vasoconstrictor effect aldosterone causes renal salt and water retention; this effect is largely nullified by the normal kidney in unilateral ARAS as a result of pressure-induced natriuresis, but causes fluid retention in bilateral ARAS (Fig 1) or in ARAS in a solitary functioning kidney (Figs 2(a) and (b)).
Confounders
ARAS is a marker of severe generalised atherosclerosis which usually develops in a setting of long-standing essential hypertension. Many patients will also have significant parenchymal renal damage that will be contributing to the hypertension. Clearly, successful intervention can at best improve blood pressure (BP) control.
Clinical clues
An obvious pointer is sudden worsening of previously well controlled BP in a patient known to have vascular disease. Although ACEI/AIIRA will probably significantly reduce GFR in the affected kidney in unilateral ARAS, this may not be reflected in serum creatinine (SCr) if the contralateral kidney has good function. An increase in SCr of up to 30% following introduction of ACEI is common in the setting of chronic renal failure (CRF) of any cause. It simply reflects reduction of glomerular perfusion in the remaining nephrons which, in the presence of hyperperfusion, is protective against further nephron damage. 2 
Evidence
Studies of revascularisation for ARAS show very low cure rates and relatively minor improvements in BP, in sharp contrast to the good results of revascularisation for fibromuscular dysplasia (Fig 3) . 3, 4 It is possible that substantial benefit in a small proportion of individuals is not revealed in trials that have to look at group outcomes.
RECOMMENDATION: investigation is recommended in (a) long-standing hypertensives with recent worsening of BP control and evidence of atheromatous vascular disease in any organ, and (b) hypertensives whose SCr rises by more than 30% after introduction of an ACEI/AIIRA.
ARAS as a cause of renal impairment 1 Progressive chronic renal failure
Theoretical background
This is an area in which there is controversy. Indisputably, ARAS can progress to renal artery occlusion (RAO). degree of stenosis. A kidney beyond an RAO usually atrophies if renal blood flow is not restored, although collateral circulation often prevents immediate infarction. Hypothetically, ARAS (not RAO) can cause 'ischaemic nephropathy' (gradual nephron loss due to poor blood supply), but this theory is increasingly discredited. Gradual nephron loss is not usually seen despite very tight stenoses in fibromuscular diseases of the renal artery, so poor blood supply in itself seems an inadequate explanation for the CRF often seen in ARAS. CRF progressing over months to years is not likely to be due to ARAS.
ARAS can cause end-stage renal failure (ESRF) if both renal arteries become occluded. The problem for the clinician is that those most at risk (one artery occluded, the other stenosed) are likely to have stable renal function until late in the evolution of the stenosis. Renal function beyond a very tight stenosis becomes inversely proportional to blood pressure; these patients may also develop recurrent pulmonary oedema or ACEIinduced acute renal failure (ARF) (see below).
Although it is highly likely that revascularisation might reduce the risk of RAO in some patients with severe ARAS, even without intervention these patients are much more likely to die of nonrenal vascular disease than reach ESRF. 5, 6 Confounders Recent studies have shown that progressive CRF and ARAS often coexist even with unilateral ARAS. Individual kidney GFR estimations show function to be:
as bad in nonstenosed kidneys unrelated to the degree of stenosis, and unchanged after revascularisation (Fig 4) . [7] [8] [9] 522 Clinical Medicine Vol 3 No 6 November/December 2003 CME Renal Medicine Var.
Difference and CI Angioplasty Medical therapy CRF appears to result not from the stenosis but from a combination of hypertensive nephropathy and so-called 'athero-embolic nephropathy' in which the renal damage is due to cholesterol and athero-emboli arising from the diseased aorta.
Clinical clues
ACEI/AIIRA in bilateral ARAS (most commonly occlusion on one side and a stenosis on the other) normally produces a rapid large rise in SCr from a normal or slightly elevated baseline. In bilateral ARAS, GFR becomes proportional to systemic BP, and any drug which produces a significant drop in BP will also elevate SCr. Lack of progression of CRF does not rule out significant bilateral ARAS -or indeed progression of the stenosis.
Ultrasonography may show renal asymmetry as a pointer to unilateral RAO. Gradually progressive CRF is more likely to point to athero-embolic nephropathy than to worsening ARAS.
Evidence
There are numerous claims of renal functional improvement or stabilisation after intervention in CRF, but these are variously flawed. 10 Good BP control and attending a nephrology clinic have both been shown to stabilise CRF, so the contribution of intervention to apparent improvement is often unclear. On theoretical grounds, those most likely to benefit will have a tight stenosis to a solitary but well functioning kidney. As the stenosed kidney still has good function, successful intervention will have little impact on baseline SCr. The benefit (reduced risk of RAO, and therefore of ESRF) is not discernible in individuals. Proof that intervention is worthwhile would require a randomised controlled comparison of intervention versus medical treatment, with follow-up to death or ESRF. ASTRAL, the largest ever randomised trial of intervention in ARAS is currently underway in the UK. 11 This may shed light on the relative risks and benefits of intervention in the various settings described here.
A common finding in most studies is that the likelihood of stabilisation of renal function diminishes with the degree of renal impairment. This supports the theory that ARAS is seldom the cause of CRF even when both problems coexist.
The future
The pressure to intervene has recently increased as the benefits of ACEI become clear. Many patients with ARAS fulfil criteria for treatment with ACEI to reduce their risk of cardiovascular events. 12 In the presence of bilateral ARAS, however, an adequate dose of ACEI normally causes ARF. Successful revascularisation often allows safe institution of ACEI therapy, although there is unlikely ever to be a randomised controlled trial to prove that revascularisation to allow the introduction of ACEI is beneficial.
RECOMMENDATION: investigation is indicated in patients with an ACEI or AIIRA induced rise in SCr of more than 30%, especially if not associated with hypotension.
Sudden onset oligo-anuric renal failure
Theoretical background
When the stenosis to a solitary functioning kidney progresses to occlusion, renal blood flow becomes insufficient to maintain GFR. The occlusion occurs after prolonged ARAS, so renal collaterals are sufficiently developed to prevent immediate renal infarction; revascularisation within a few days can restore renal function.
Clinical clues
The patient is typically oliguric, hypertensive and increasingly oedematous (pulmonary and/or peripheral). SCr rises by about 200-300 µmol/l per day. Loin pain is rare, but when it occurs may indicate infarction and therefore predict a poor response to revascularisation. Occlusion can be precipitated by relatively minor hypotensive episodes, and the diagnosis should be considered when ARF follows apparently straightforward surgery. A new onset oligo-anuric renal failure is an absolute indication for urgent nephrological referral, but this rare cause is unlikely to be missed by a general physician.
Evidence
There are several anecdotal reports of good sustained recovery of renal function. 13 The enthusiasm for reporting reflects the gratifying response to intervention rather than the incidence. (Table 2) .
Clinical Medicine
Pulmonary oedema
Theoretical background
In bilateral ARAS (or unilateral ARAS plus a nonfunctioning contralateral kidney), excess AII and aldosterone production and failure of pressure-natriuresis cause severe hypertension, fluid retention and often dramatic onset pulmonary oedema -frequently aggravated by left ventricular (LV) impairment secondary to hypertension and/or coronary artery disease.
Clinical clues
Pulmonary oedema in a hypertensive arteriopath is not unreasonably usually assumed to be caused by LV failure. With the widespread introduction of ACEI for LV failure, most cases of pulmonary oedema due to bilateral ARAS should be unmasked by a big rise in SCr within a few days of starting ACEI. Other nonspecific clues include well preserved LV function on echocardiography and high BP.
Confounders
Low output heart failure causes poor renal perfusion. ACEI commonly raises SCr in this setting.
Evidence
The frequency of anecdotal reports again reflects spectacular benefit rather than incidence. 14 RECOMMENDATION: renal artery imaging should be performed when SCr rises more than 30% after starting ACEI/AIIRA treatment for pulmonary oedema in the absence of hypotension due to low output heart failure ( Table 2) .
Incidental findings
There are two common ways in which ARAS is incidentally unmasked: 
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